Li-Fraumeni Syndrome
18
9
10
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (18)
Clinical Genetics Branch Eligibility Screening Survey
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Clinical and Genetic Studies of Li-Fraumeni Syndrome
Li-Fraumeni Syndrome Imaging Study
Familial Investigations of Childhood Cancer Predisposition
Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes
Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome
Registry of Li Fraumeni and Li Fraumeni Like Syndromes
Li-Fraumeni Syndrome/TP53 Biobank
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53
Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome
Biomarker Monitoring in TP53 Mutation Carriers